Granules India Ltd-$
Q1 FY27, unaudited
- Revenue
- ₹1,476.77 Cr
- Profit after tax
- ₹179.96 Cr
As filed with the exchange, consolidated basis.
Statement of profit and loss
Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.
| ₹ crore | Q1 FY27 | vs a year ago | FY26 |
|---|---|---|---|
| Revenue from operations | 1,476.77 | +22.04% | 5,365.64 |
| Other income | 2.27 | −86.13% | 20.33 |
| Total income | 1,479.04 | +20.60% | 5,385.97 |
| Employee benefit expense | 254.57 | +25.55% | 888.36 |
| Finance costs | 21.12 | −11.17% | 114.35 |
| Depreciation & amortisation | 79.65 | +15.69% | 296.14 |
| Total expenses | 1,238.64 | +17.29% | 4,590.99 |
| Profit before tax | 240.40 | +66.34% | 784.98 |
| Tax expense | 60.44 | +89.54% | 189.96 |
| Profit after tax | 179.96 | +59.77% | 595.02 |
| Total comprehensive income | 210.02 | +59.52% | 738.34 |
| Earnings per share, basic | ₹7.26 | ₹24.47 |
|---|---|---|
| Earnings per share, diluted | ₹7.12 | ₹24.46 |
Earnings call
Q1 FY27Granules India reported Q1 FY27 revenue of about Rs 1,477 crore, up 22% year-on-year, with EBITDA growing 37% to Rs 339 crore and profit after tax up 60% to Rs 180 crore. Management said complex generics now form about 50% of finished dosages compared to 39% a year earlier, and the peptide CDMO business grew more than 100% year-on-year. The company also stated that remediation work at its Gagillapur facility is essentially complete, with the FDA having raised no concerns on the pace or adequacy of corrective actions to date.
Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary
Earlier calls: Q4 FY26 · All quarters
Filings
12 shown · 37 published by the exchange
13 Aug 2026
Filing06 Aug 2026
06 Aug 2026
04 Aug 2026
27 Jul 2026
22 Jul 2026
21 Jul 2026
Filing21 Jul 2026
Presentation21 Jul 2026
21 Jul 2026
16 Jul 2026
Filing15 Jul 2026
BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.
Page generated from filings held to 13 Aug 2026.